Retroviruses : Rethinking Mast Cell Activation

July 23, 2018  |  Blog

For some time now, I have been studying retroviruses and their link to chronic illnesses, including mast cell activation syndrome and chronic fatigue syndrome.

Retroviruses trigger the cell danger response or mast cell activation.

I started by following the work of  Dr. Judy Mikovits whose ground-breaking research, identified that retroviruses were linked to many chronic illnesses.

She outlined her research in the ground-breaking book Plague: One Scientists Intrepid Search for the Truth about Human Retroviruses and Chronic Fatigue Syndrome (ME/CFS), Autism, and Other Diseases.

From there I was mentored by a functional practitioner with access to Dr. Judy Mikovits on her recommended retrovirus protocol. I’ve implemented this protocol with some clients with chronic illnesses with profound results.

More recently, Dr. Klinghardt, who I have trained with has started teaching his approach to retroviruses.

His approach is based on the work of Dr. Mikovits but brings with it extensive clinical experience. Dr. Klinghardt uses a form of applied kinesiology called ART to individualize solutions. I find his methods extremely accurate and am increasingly using it with all my clients.

This work has the capacity to change the way we address chronic illness and specifically mast cell activation, chronic fatigue syndrome, and the cell danger response in general.

What are retroviruses?

As humans, we all have retroviruses.

In fact, retroviruses are estimated to make up to 8 -15% of our DNA, having been passed down to us by our ancestors, so more than our protein (genetic) DNA.

Most people live in harmony with retroviruses. Dr. Mikovits estimates that only 5% of the population are at risk of chronic illness from them through a compromised immune system.

The more familiar viruses, epstein barr, and the herpes family are not retroviruses.

These are DNA viruses. They reside in our DNA until they are reactivated when they then transcribe into our RNA then create viral proteins.

They do not change our DNA.  They are already part of our DNA.

In contrast, retroviruses work their way backward via the reverse transcriptase enzyme, from the RNA to DNA. From there they work forward again to the RNA where they create viral proteins.

They change our DNA to make us a good host and once in our DNA can be passed onto future generations. For example, retroviruses can change our MTHFR (or any other) genetic status.

A famous retrovirus is HIV.  However, there is a multitude of others.

Some may be beneficial, whilst others may be harmful, and involved in cancer, auto-immune disease, chronic fatigue and chronic illnesses.

Sources of Retroviruses

New retroviruses can be acquired by:

  • Human transmission (via bodily fluids and notably in hospitals) such as the flu
  • Insect bites and flea dirt
  • Vaccines (which have been found to be contaminated with animal-sourced retroviruses).

All the same, it is not the viral load that is an issue in itself, and there does not need to be a change in viral load, for chronic illness to occur.

The issue is the change in our detoxification (methylation and acetylation) or the immune system that is preventing us from silencing the retroviruses triggered by:

  • Wi-fi
  • Glyphosphate, Polysorbate 80, (and likely other chemicals)
  • Aluminum and mercury
  • Co-infections (parasites, Lyme, and Co-infections, yeast and mold)
  • Cavitations (from teeth extractions), and
  • Emotional stress.

Dr. Klinghardt’s experience is that it is unlikely to be any one item, more likely a synergy of environmental exposures. This also means that once treated, there is a risk of reactivation, if the environment does not remain clean.

Dr, Klinghardt has also found that retroviruses are also a higher order item. This means that if parasites, cavitation infections, Lyme and co-infections and so on, do not resolve on treatment that there is a higher priority. Also, that treating retroviruses make successful treatment of other issues, easier.

Laboratory Testing

No direct testing of individual retroviruses is commercially available. Furthermore, there are 100s of them so testing individually is impractical.

Instead, a test looking for overall viral loads can be used as follows:

  • Elevated Nagalase (below 0.6) – typically used alone or in combination with other markers.
  • Elevated RANTES  – a marker of the retrovirus in dental infections and cavitations.

Other tests may point to a retrovirus but these are the most accessible.

Treatment Protocols

Plant approaches are highly effective. Studies have even found that herbal approaches are even effective where medicine has failed.

Here are some of the plants in research which are effective against retroviruses.

Cistus Incantas Tea

A study in Scientific Reports from 2016 shows Cistus Incantas Tea is effective against the worst of retroviruses, and to be effective in the most drug-resistant cases.

It also has been shown to protect the DNA from retroviruses.

Cistus Incantas Tea (or drops) are the backbone to both Dr. Mikovits’ and Dr. Klinghardt’s treatment protocol. Dr. Klinghardt recommends that the tea is reused to extract all the plant’s compounds.

Broccoli Sprouts

Sulforaphane has not only been shown to have anti-viral activity but protects the cell from DNA damage.

Broccoli sprouts in their natural form are ideal although can be taken as a supplement.

If taken in their natural form they need to be chewed to convert the broccoli sprouts to sulforaphane. It’s only 1 heaped tablespoons twice a day that is needed.

Whilst this is not part of Dr. Mikovits’ protocol, it is of Dr. Klinghardt’s, and tests exceptionally well with ART testing with many of my clients.

Other Herbs Effective with Retroviruses

Other herbs that have been shown to have antiviral properties include:

  • Baicalin (Skullcap Root) Liftmode
  • St John’s Wort
  • Green Tea
  • Reishi Mushroom – ReishiMax GLP
  • Stinging Nettle
  • Olive Leaf
  • Bitter Melon
  • Pantethine (B5) – slows replication
  • Selenium – is dramatically depleted by retroviruses.
  • Luteolin – NeuroProtek®

Dr. Klinghardt sells a product that contains a mixture of herbs known to be effective with retroviruses. The product is called RetroV and supplements pantethine and selenium.

Dr.Mikovits focuses on single products, including Liftmode, which is the one that I have used successfully in retroviral protocols.

Other Considerations

The protocols outline above are anti-retroviral protocols.

The retroviruses when activated can cause dysregulation of many of the body’s systems. This is why most functional health practitioners evaluate and support the whole body.

In addition to actually deactivating the virus, Dr. Mikovits has done a considerable amount of work, around restoring homeostasis, including the endocannabinoid, microbiome (through the whole body, not just the gastrointestinal tract), and immune system.

These will be the subject of further blog posts.

Dr. Klinghardt has also done a considerable amount of work on medicines for the cell danger response which I have covered extensively in a separate blog post.

Conclusion

Retroviruses are not an issue for the majority of people.

Mikovits estimates a less than 5% lifetime chance of retroviruses causing chronic health issues. Klinghardt also highly correlates retroviruses to mast cell activation and the cell danger response in his practice.

However, if you have a chronic illness, or cannot seem to clear other pathogens, then retroviruses may be the missing link.

The area of retroviruses is an emerging area of health and both Klinghardt’s and Mitkovics’ protocols have made a profound difference to many of my clients.

 

Further Reading

Lima, Marco A., et al. “Subacute progression of human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.” Journal of Neurovirology 13.5 (2007): 468-473.

McCormick, A. L., et al. “Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate.” Neurology 70.4 (2008): 278-283.

Löwer, Roswitha, Johannes Löwer, and Reinherd Kurth. “The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences.” Proceedings of the National Academy of Sciences 93.11 (1996): 5177-5184.

Nelson, Paul N., et al. “Demystified… Human endogenous retroviruses.” Molecular Pathology 56.1 (2003): 11.

Van Der Kuyl, Antoinette Cornelia, Marion Cornelissen, and Ben Berkhout. “Of mice and men: on the origin of XMRV.” Frontiers in Microbiology 1 (2011): 147.

Fragopoulou, Adamantia F., et al. “Brain proteome response following whole body exposure of mice to mobile phone or wireless DECT base radiation.” Electromagnetic biology and medicine 31.4 (2012): 250-274.

Mechoulam, Raphael, et al. “Cannabidiol–recent advances.” Chemistry & Biodiversity 4.8 (2007): 1678-1692.

Castillo, Pablo E., et al. “Endocannabinoid signaling and synaptic function.” Neuron 76.1 (2012): 70-81.

Singh, Kanwaljit, and Andrew W Zimmerman. “Sulforaphane treatment of young men with autism spectrum disorder.” CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 15.5 (2016): 597-601.

Singh, Kanwaljit, et al. “Sulforaphane treatment of autism spectrum disorder (ASD).” Proceedings of the National Academy of Sciences 111.43 (2014): 15550-15555.

Tester, Jodie, and Tessa Finney-Brown. “Sulforaphane treatment of autism spectrum disorder.” Australian Journal of Herbal Medicine 27.1 (2015): 41.

Armah, Charlotte N., et al. “A diet rich in high-glucoraphanin broccoli interacts with genotype to reduce discordance in plasma metabolite profiles by modulating mitochondrial function–.” The American journal of clinical nutrition 98.3 (2013): 712-722.

Yang, Li, Dushani L. Palliyaguru, and Thomas W. Kensler. “Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane.” Seminars in oncology. Vol. 43. No. 1. WB Saunders, 2016.

Heiss, Elke, et al. “Nuclear factor-?B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms.” Journal of Biological Chemistry (2001).

Gan, Nanqin, et al. “Sulforaphane activates heat shock response and enhances proteasome activity through up-regulation of Hsp27.” Journal of Biological Chemistry 285.46 (2010): 35528-35536.

Rebensburg, Stephanie, et al. “Potent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins.” Scientific reports 6 (2016): 20394.

Attaguile, G., et al. “Antioxidant activity and protective effect on DNA cleavage of extracts from Cistus incanus L. and Cistus monspeliensis L.” Cell biology and toxicology 16.2 (2000): 83-90.

Ehrhardt, Christina, et al. “A polyphenol-rich plant extract, CYSTUS052, exerts anti-influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance.” Antiviral research 76.1 (2007): 38-47.

Li, B. Q., et al. “Inhibition of HIV infection by baicalin–a flavonoid compound purified from Chinese herbal medicine.” Cellular & molecular biology research 39.2 (1993): 119-124.

Zhao, Qing, et al. “A specialized flavone biosynthetic pathway has evolved in the medicinal plant, Scutellaria baicalensis.” Science advances 2.4 (2016): e1501780.

Meruelo, Daniel, Gad Lavie, and David Lavie. “Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin.” Proceedings of the National Academy of Sciences 85.14 (1988): 5230-5234.

Nakane, Hideo, Yukihiko Hara, and Katsuhiko Ono. “Tea polyphenols as a novel class of inhibitors for human immunodeficiency virus reverse transcriptase.” ACS symposium series (USA). 1994.

Min, Byung-Sun, et al. “Triterpenes from the spores of Ganoderma lucidum and their inhibitory activity against HIV-1 protease.” Chemical and Pharmaceutical Bulletin 46.10 (1998): 1607-1612.

Gao, Yihuai, and Shufeng Zhou. “Cancer prevention and treatment by Ganoderma, a mushroom with medicinal properties.” Food Reviews International 19.3 (2003): 275-325.

Sliva, Daniel, et al. “Biologic activity of spores and dried powder from Ganoderma lucidum for the inhibition of highly invasive human breast and prostate cancer cells.” The Journal of Alternative & Complementary Medicine 9.4 (2003): 491-497.

Slivova, Veronika. “Ganoderma lucidum inhibits invasiveness of breast cancer cells.” J Cancer Integr Med 2 (2004): 25-30.

Balzarini, Jan, et al. “The mannose-specific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (N-acetylglucosamine) n-specific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replication in vitro.” Antiviral research 18.2 (1992): 191-207.

Lee-Huang, Sylvia, et al. “Anti-HIV activity of olive leaf extract (OLE) and modulation of host cell gene expression by HIV-1 infection and OLE treatment.” Biochemical and Biophysical Research Communications 307.4 (2003): 1029-1037.

Ng, T. B., et al. “Isolation and characterization of a galactose-binding lectin with insulinomimetic activities: from the seeds of the bitter gourd Momordica charantia (family Cucurbitaceae).” International journal of peptide and protein research 28.2 (1986): 163-172.
Kristensson, Krister. “Microbes’ roadmap to neurons.” Nature Reviews Neuroscience 12.6 (2011): 345.
Ko, Yeon-Ju, et al. Flavonoids as potential inhibitors of retroviral enzymes. Journal of the Korean Society for Applied Biological Chemistry 52.4 (2009): 321-326.
Mehla, Rajeev, Shalmali Bivalkar-Mehla, and Ashok Chauhan. “A flavonoid, luteolin, cripples HIV-1 by abrogation of tat function.” PLoS One 6.11 (2011): e27915.
Paterniti, Irene, et al. “Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer’s disease models: the control of neuroinflammation.” CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 13.9 (2014): 1530-1541.
Bologna, Rosa, et al. “Selenium and immunity in HIV-1 infected pediatric patients.” Journal of Nutritional immunology3.1 (1994): 41-49.
Baum, Marianna K., et al. “High risk of HIV-related mortality is associated with selenium deficiency.” JAIDS Journal of Acquired Immune Deficiency Syndromes 15.5 (1997): 370-374.
Campa, Adriana, et al. “Mortality risk in selenium-deficient HIV-positive children.” Journal of acquired immune deficiency syndromes and human retrovirology: official publication of the International Retrovirology Association 20.5 (1999): 508-513.
Cirelli, Augusto, et al. “Serum selenium concentration and disease progress in patients with HIV infection.” Clinical Biochemistry 24.2 (1991): 211-214.
Dworkin, Brad M. “Selenium deficiency in HIV infection and the acquired immunodeficiency syndrome (AIDS).” Chemico-biological interactions 91.2-3 (1994): 181-186.
Schrauzer, Gerhard N., and Juliane Sacher. “Selenium in the maintenance and therapy of HIV-infected patients.” Chemico-Biological Interactions 91.2-3 (1994): 199-205.
Baeten, Jared M., et al. “Selenium deficiency is associated with shedding of HIV-1–infected cells in the female genital tract.” Journal of acquired immune deficiency syndromes (1999) 26.4 (2001): 360-364.
Enjoyed This Post?
Sign up for Monthly Updates. Its FREE!
Print This Post Print This Post